These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10078726)

  • 21. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
    Boyce S; Rupniak NM; Steventon MJ; Iversen SD
    Neurology; 1990 Jun; 40(6):927-33. PubMed ID: 2140595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
    Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
    Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
    Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    Jpn J Pharmacol; 1995 Feb; 67(2):117-24. PubMed ID: 7616686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
    Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
    Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
    Schneider JS
    Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
    Hadj Tahar A; Bélanger N; Bangassoro E; Grégoire L; Bédard PJ
    Eur J Pharmacol; 2000 Jul; 399(2-3):183-6. PubMed ID: 10884518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
    Arai N; Isaji M; Kojima M; Mizuta E; Kuno S
    J Neural Transm (Vienna); 1996; 103(11):1307-16. PubMed ID: 9013417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.
    Hadj Tahar A; Grégoire L; Bangassoro E; Bédard PJ
    Clin Neuropharmacol; 2000; 23(4):195-202. PubMed ID: 11020123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys.
    Doan VD; Grondin R; Hadj Tahar A; Grégoire L; Bédard PJ
    Clin Neuropharmacol; 1999; 22(5):281-7. PubMed ID: 10516879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys.
    Herrero MT; Augood SJ; Asensi H; Hirsch EC; Agid Y; Obeso JA; Emson PC
    Brain Res Mol Brain Res; 1996 Nov; 42(1):149-55. PubMed ID: 8915594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.